Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146169 | 0.93 | MASP2 (0.48) | MASP2AKT1ROCK2PIM1PRKACA | |
| Hydrochloric Acid SCHEMBL1902944 | 0.92 | MASP2 (0.48) | MASP2AKT1ROCK2PIM1PRKACA | |
| Trifluoroacetic Acid SCHEMBL1906333 | 0.83 | DRD2 (0.44) | OPRK1AKT1ROCK2PIM1PRKACA | |
| Trifluoroacetic Acid SCHEMBL1432755 | 0.83 | MME (0.48) | MASP2OPRD1 | |
| SCHEMBL3156487 | 0.83 | MASP2 (0.47) | MASP2NAMPT | |
| SCHEMBL3154431 | 0.82 | MASP2 (0.56) | MASP2NLNNAMPT | |
| SCHEMBL3155167 | 0.81 | MASP2 (0.49) | MASP2NLNNAMPT | |
| Trifluoroacetic Acid SCHEMBL18787097 | 0.81 | KMT2A (0.50) | OPRK1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL18787095 | 0.81 | KMT2A (0.50) | OPRK1OPRD1 | |
| SCHEMBL7860770 | 0.79 | EGFR (0.53) | AKT1ROCK2PIM1PRKACAFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011051671-A1 | AMINOPYRIDINE DERIVATIVES AS KALLIKREIN INHIBITORS | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MASP2 3039/4885OPRK1 161/4885AKT1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.